The company said it exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, on July 15, 2024. It said the move followed its initial investment in 2017.

8-KRegulation FD DisclosureFiled Jul 15, 2024Period of report Jul 15, 2024Summary published (UTC) Oct 26, 2026

Key points

AI summary

The company said it exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, on July 15, 2024. It said the move followed its initial investment in 2017.
Edwards said it expects to pay about $300 million in cash at closing of its Innovalve acquisition. The company said it expects the acquisition to close by the end of 2024.
The company said Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president Daveen Chopra. Chopra said the SAPIEN M3 is on track to become the first approved transfemoral TMVR system in Europe by the end of 2025.
The company disclosed risk factors, including that it may be unable to close the Innovalve acquisition in a timely manner or at all, uncertainty over the timing of closing, and potentially significant transaction costs.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Edwards Exercises Option to Acquire Innovalve Bio Medical Ltd.

The company said it exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, on July 15, 2024. It said the move followed its initial investment in 2017.

Source · Based on the filing body and exhibits

About $300 million in Cash Expected at Closing

Edwards said it expects to pay about $300 million in cash at closing of its Innovalve acquisition. The company said it expects the acquisition to close by the end of 2024.

Source · Based on the filing body and exhibits

TMTT Product Group Addition and SAPIEN M3 Timeline

The company said Innovalve will join the transcatheter mitral and tricuspid therapies (TMTT) product group, led by corporate vice president Daveen Chopra. Chopra said the SAPIEN M3 is on track to become the first approved transfemoral TMVR system in Europe by the end of 2025.

Source · Based on the filing body and exhibits

Risk Factors Related to Innovalve Acquisition Closing

The company disclosed risk factors, including that it may be unable to close the Innovalve acquisition in a timely manner or at all, uncertainty over the timing of closing, and potentially significant transaction costs.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.